Epidermal growth factor receptor inhibition strategies in oncology.
about
Breast cancer chemoprevention: old and new approachesGastrointestinal neuroendocrine tumors: pancreatic endocrine tumorsEfficacy of targeted drugs in germ cell cancer cell lines with differential cisplatin sensitivity.Nonlinear pharmacokinetics of therapeutic proteins resulting from receptor mediated endocytosisPopulation pharmacokinetic data analysis of three phase I studies of matuzumab, a humanised anti-EGFR monoclonal antibody in clinical cancer developmentEpidermal growth factor receptor mutation in combination with expression of MIG6 alters gefitinib sensitivity.PET imaging of HER1-expressing xenografts in mice with 86Y-CHX-A''-DTPA-cetuximab.Preparation, biological evaluation, and pharmacokinetics of the human anti-HER1 monoclonal antibody panitumumab labeled with 86Y for quantitative PET of carcinomaSystemic radiotherapy can cure lymphoma: a paradigm for other malignancies?EGFR-mutated lung cancer: a paradigm of molecular oncology.The influence of adnectin binding on the extracellular domain of epidermal growth factor receptor.Characteristics of triple-negative breast cancerGrowth suppression of human hepatocellular carcinoma xenografts by a monoclonal antibody CH12 directed to epidermal growth factor receptor variant IIITyrosine kinase inhibitors: Multi-targeted or single-targeted?The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells.Impact of oncogenic K-RAS on YB-1 phosphorylation induced by ionizing radiation.Radioimmunotargeting of malignant glioma by monoclonal antibody D2C7 reactive against both wild-type and variant III mutant epidermal growth factor receptorsA novel small molecule that selectively inhibits glioblastoma cells expressing EGFRvIII.Radiotherapy and erlotinib combined: review of the preclinical and clinical evidenceEvaluation of cetuximab as a candidate for targeted α-particle radiation therapy of HER1-positive disseminated intraperitoneal disease.Feasibility of eradication of breast cancer cells remaining in postlumpectomy cavity and draining lymph nodes following intracavitary injection of radioactive immunoliposomesMitogenic signal transduction pathways in meningiomas: novel targets for meningioma chemotherapy?Research progress on criteria for discontinuation of EGFR inhibitor therapy.Emerging role of tyrosine kinase inhibitors in the treatment of advanced renal cell cancer: a review.Future chemotherapy and radiotherapy options in head and neck cancer.Molecular biology of epidermal growth factor receptor inhibition for cancer therapy.Blood-brain barrier and chemotherapeutic treatment of brain tumors.Vandetanib (ZD6474): an orally available receptor tyrosine kinase inhibitor that selectively targets pathways critical for tumor growth and angiogenesis.The new paradigm in the treatment of colorectal cancer: are we hitting the right target?Quantification of epidermal growth factor receptor expression level and binding kinetics on cell surfaces by surface plasmon resonance imagingNovel antibodies as anticancer agents.Emerging drugs for targeted therapy of bladder cancer.Cetuximab: preclinical evaluation of a monoclonal antibody targeting EGFR for radioimmunodiagnostic and radioimmunotherapeutic applications.Targeting epidermal growth factor receptor and SRC pathways in head and neck cancerEpidermal growth factor receptor and cancer: control of oncogenic signalling by endocytosisThe effects of DNA formulation and administration route on cancer therapeutic efficacy with xenogenic EGFR DNA vaccine in a lung cancer animal model.Simultaneous EGFR and VEGF alterations in non-small cell lung carcinoma based on tissue microarrays.Role of ErbB family receptor tyrosine kinases in intrahepatic cholangiocarcinomaBiomarkers predicting clinical outcome of epidermal growth factor receptor-targeted therapy in metastatic colorectal cancer.Quantitative proteomic profiling identifies protein correlates to EGFR kinase inhibition
P2860
Q27693259-C3D1DC10-675B-44C7-9C50-502058709668Q28290833-E1637075-B345-4A66-8C2C-3D4C22E3BA1BQ30313117-B3F038E4-6543-434C-9944-5C0BD4DEE110Q30489162-780B2D05-BEB3-4058-B3A7-601433FE473AQ31148686-52889CF9-0309-46B7-9325-2AAAFAC09851Q33824203-6DF0A4FE-A926-4965-BE9E-31B1656FD2D9Q33939881-53939443-73BE-4974-A194-50E7EBFE8152Q33943630-6371EEAD-3881-4BA4-9E77-6305D895B6EEQ34335207-0D0A92C3-1401-4094-876E-97FB7777FE2BQ34406334-FDDBB705-7B1D-41DA-910D-427C8844CC4DQ34474034-4F8A23FB-64CA-49DB-8A2D-9E24A425B6C7Q34479003-5E6503B0-7322-4A19-B12D-08EF396F03BCQ34568677-898DECEC-E139-4058-9248-8FD7459C9AD5Q34983846-3BE4395A-245E-48E5-8599-EBB4B811DA95Q35469548-4B05FF0B-777F-4916-8ACE-506877C44F04Q35558949-83E5A32F-8109-4034-8A88-72554681D268Q35659088-6BBFD976-01AC-451D-9B34-2AD9CB292CD4Q35757512-D4EB362F-4DDA-46AA-AABA-AB5433E27840Q35970960-D72F755C-9B76-446A-9EB2-7CBABA155EF8Q36213374-AD253AB1-16CF-4856-9311-06545BA6E8AEQ36239594-E41D704D-046D-45F7-8A10-6D81A767F228Q36327729-9F66889E-2BCE-4E1C-9A96-856F06436A81Q36330264-36F5459E-E914-41F6-B23B-58D8215CCC1CQ36370992-7C3D69B9-AD53-4434-A30D-6BCD05E4511EQ36407462-A7B72C91-572F-4ABD-8C92-A980932FB503Q36481002-F51520EE-46FD-496A-AC42-9A2564C6853AQ36558683-B69DC023-8C14-45E9-9004-E3720AEC83A2Q36715777-18BC7DA4-11FD-4261-BE81-F36A8A7EA975Q36736346-B5A403FB-FF4C-460C-A8FD-CD2BA577B076Q36813117-DB306851-0E79-4A60-901A-F728D802EEDAQ36832141-E1235D35-C390-4C6F-9E28-007A193C7DEDQ36944022-2FE13623-05B1-44B2-A00A-C378F5DA66C3Q36982489-96741B9D-6AF0-4FC0-862F-B897F50E1F70Q36983136-84892889-C15A-47AC-BD8A-7F11B38453ACQ37101643-69327525-BA57-415C-83CB-CA552C15E7CFQ37103859-A83C2D93-4056-4115-BDD4-61130D1FF126Q37175922-3BF025D1-D0D1-4B58-8817-04A70F4A64E1Q37351498-62D6F84E-38AE-445E-80B7-8DE4EEB0EAD8Q37378581-213AFC5C-C9C2-4AE8-A4EF-C909864D8836Q37649220-DA2ABF4D-CE04-4759-B5C4-FB9D8A147F64
P2860
Epidermal growth factor receptor inhibition strategies in oncology.
description
2004 nî lūn-bûn
@nan
2004 թուականի Դեկտեմբերին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի դեկտեմբերին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Epidermal growth factor receptor inhibition strategies in oncology.
@ast
Epidermal growth factor receptor inhibition strategies in oncology.
@en
Epidermal growth factor receptor inhibition strategies in oncology.
@nl
type
label
Epidermal growth factor receptor inhibition strategies in oncology.
@ast
Epidermal growth factor receptor inhibition strategies in oncology.
@en
Epidermal growth factor receptor inhibition strategies in oncology.
@nl
prefLabel
Epidermal growth factor receptor inhibition strategies in oncology.
@ast
Epidermal growth factor receptor inhibition strategies in oncology.
@en
Epidermal growth factor receptor inhibition strategies in oncology.
@nl
P356
P1476
Epidermal growth factor receptor inhibition strategies in oncology.
@en
P2093
P M Harari
P304
P356
10.1677/ERC.1.00600
P577
2004-12-01T00:00:00Z